P. Mistry et al., In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, CANCER RES, 61(2), 2001, pp. 749-758
The overexpression of P-glycoprotein (P-gp) on the surface of tumor cells c
auses multidrug resistance (MDR), This protein acts as an energy-dependent
drug efflux pump reducing the intracellular concentration of structurally u
nrelated drugs. Modulators of P-gp function can restore the sensitivity of
MDR cells to such drugs. XR9576 is a novel anthranilic acid derivative deve
loped as a potent and specific inhibitor of P-gp, and in this study we eval
uate the irt vitro and in vivo modulatory activity of this compound. The in
vitro activity of XR9576 was evaluated using a panel of human (H69/LX4, 27
80AD) and murine (EMT6 AR1.0, MC2B) MDR cell lines. XR9576 potentiated the
cytotoxicity of several drugs including doxorubicin, paclitaxel, etoposide,
and vincristine; complete reversal of resistance was achieved in the prese
nce of 25-80 nM XR9576, Direct comparative studies with other modulators in
dicated that XR9576 was one of the most potent modulators described to date
, Accumulation and efflux studies with the P-gp substrates, [H-3]daunorubic
in and rhodamine 123, demonstrated that XR9576 inhibited P-gp-mediated drug
efflux, The inhibition of P-gp function was reversible, but the effects pe
rsisted for >22 h after removal of the modulator from the incubation medium
. This is in contrast to P-gp substrates such as cyclosporin A and verapami
l, which lose their activity within (10 min, suggesting that XR9576 is not
transported by P-gp, Also, XR9576 was a potent inhibitor of photoaffinity l
abeling of P-gp by [H-3]azidopine implying a direct interaction with the pr
otein, In mice bearing the intrinsically resistant MC26 colon tumors, coadm
inistration of XR9576 potentiated the antitumor activity of doxorubicin wit
hout a significant increase in toxicity; maximum potentiation was observed
at 2.5-4.0 mg/kg dosed either i.v. or p.o. In addition, coadministration of
XR9576 (6-12 mg/kg p.o.) fully restored the antitumor activity of paclitax
el, etoposide, and vincristine against two highly resistant MDR human tumor
xenografts f2780AD, H69/LX4) in nude mice, Importantly all of the efficaci
ous combination schedules appeared to be well tolerated, Furthermore, i.v.
coadministration of XR9576 did not alter the plasma pharmacokinetics of pac
litaxel, These results demonstrate that XR9576 is an extremely potent, sele
ctive, and effective modulator with a long duration of action. It exhibits
potent i.v. and p.o., activity without apparently enhancing the plasma phar
macokinetics of paclitaxel or the toxicity of coadministared drugs. Hence,
XR9576 holds great promise for the treatment of P-gp-mediated MDR cancers.